About Vigene Biosciences
Vigene Biosciences is a company based in Rockville (United States) founded in 2012 was acquired by Charles River Laboratories in May 2021.. Vigene Biosciences has raised $10.5 million across 2 funding rounds from investors including Charles River Laboratories and Signet Healthcare Partners. The company has 45 employees as of December 31, 2018. Vigene Biosciences has completed 1 acquisition, including Omnia Biologics. Vigene Biosciences offers products and services including Plasmid DNA Manufacturing, Viral Vector Manufacturing, Cell Therapy Manufacturing, Viral Vector Packaging, and Custom Cloning. Vigene Biosciences operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Rockville, United States
- Employees 45 as on 31 Dec, 2018
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vigene Biosciences, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$10.5 M (USD)
in 2 rounds
-
Latest Funding Round
$3 M (USD), Series A
Mar 27, 2020
-
Investors
Charles River Laboratories
& 1 more
-
Employee Count
45
as on Dec 31, 2018
- Investments & Acquisitions
-
Acquired by
Charles River Laboratories
(May 17, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vigene Biosciences
Vigene Biosciences offers a comprehensive portfolio of products and services, including Plasmid DNA Manufacturing, Viral Vector Manufacturing, Cell Therapy Manufacturing, Viral Vector Packaging, and Custom Cloning. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Produces plasmid DNA for gene therapy applications to support research and development.
Develops viral vectors for delivering gene therapies in clinical and commercial settings.
Manufactures cell-based therapies for treating various diseases through advanced processes.
Packages viral vectors to ensure stability and efficacy for therapy applications.
Provides customized cloning services for biotechnology and therapeutic research needs.
Unlock access to complete
Funding Insights of Vigene Biosciences
Vigene Biosciences has successfully raised a total of $10.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $3.0M
-
First Round
First Round
(15 May 2019)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2020 | Amount | Series A - Vigene Biosciences | Valuation |
investors |
|
| May, 2019 | Amount | Series A - Vigene Biosciences | Valuation | Signet Healthcare Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Vigene Biosciences
Vigene Biosciences has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Charles River Laboratories and Signet Healthcare Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in North America and Europe
|
Founded Year | Domain | Location | |
|
Provider of drug discovery and preclinical development services
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vigene Biosciences
Vigene Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Omnia Biologics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Process development and manufacturing services for biologics are provided.
|
2001 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Vigene Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vigene Biosciences Comparisons
Competitors of Vigene Biosciences
Vigene Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vigene Biosciences
Frequently Asked Questions about Vigene Biosciences
When was Vigene Biosciences founded?
Vigene Biosciences was founded in 2012 and raised its 1st funding round 7 years after it was founded.
Where is Vigene Biosciences located?
Vigene Biosciences is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Who is the current CEO of Vigene Biosciences?
Zairen Sun is the current CEO of Vigene Biosciences.
Is Vigene Biosciences a funded company?
Vigene Biosciences is a funded company, having raised a total of $10.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $7.5M, raised on May 15, 2019.
How many employees does Vigene Biosciences have?
As of Dec 31, 2018, the latest employee count at Vigene Biosciences is 45.
What does Vigene Biosciences do?
Vigene Biosciences was founded in 2012 in Rockville, United States, and operates within the life sciences sector. Reagents for drug discovery and functional genomics are developed, with a portfolio that includes adeno-associated virus products, lentiviruses, human cDNA clones, mammalian expression vectors, and molecular bioreagents. Services provided encompass plasmid and adenoviral cloning, lentiviral cloning, AAV packaging, TALE nuclease design, and shRNA cloning, supporting research in biotechnology applications.
Who are the top competitors of Vigene Biosciences?
Vigene Biosciences's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does Vigene Biosciences offer?
Vigene Biosciences offers Plasmid DNA Manufacturing, Viral Vector Manufacturing, Cell Therapy Manufacturing, Viral Vector Packaging, and Custom Cloning.
How many acquisitions has Vigene Biosciences made?
Vigene Biosciences has made 1 acquisition, including Omnia Biologics.
Who are Vigene Biosciences's investors?
Vigene Biosciences has 2 investors. Key investors include Charles River Laboratories, and Signet Healthcare Partners.